CLNN

Clene Inc. (CLNN) 2025 Annual Report Summary

Business Context and Reporting Period

This Form 10-K covers the fiscal year ended December 31, 2025. Clene Inc. is a clinical-stage pharmaceutical company developing Clean-Surfaced Nanotechnology (CSN) therapeutics, primarily targeting neurodegenerative diseases including Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Parkinson's Disease (PD). The company's lead asset, CNM-Au8, is a catalytically-active gold nanocrystal suspension designed to restore cellular energy metabolism. Clene currently generates minimal revenue from dietary supplements and has not yet commercialized any drug candidates.

Key Financial Metrics (Year Ended Dec 31, 2025)

Note: Revenue is derived primarily from dietary supplement sales and royalties via a related party agreement with 4Life Research LLC.

Material Changes vs. Prior Period

• Reduced Losses: Net loss decreased by 34% to $26.2 million, driven by a 30% reduction in operating expenses due to cost-saving initiatives, including reduced personnel and manufacturing costs.
• Revenue Decline: Total revenue decreased 42% to $0.2 million, attributed to timing differences in sales of dietary supplements to related parties.
• Cash Burn: Cash and cash equivalents declined by approximately $7.0 million year-over-year, leaving the company with $5.2 million as of year-end.
• Grant Revenue: Grant revenue recognized as a reduction of R&D expenses increased significantly (159%) to $8.5 million, largely due to the NIH-funded ACT-EAP program for ALS.

Guidance, Outlook, and Risks

Regulatory Pathway (ALS): Clene plans to submit a New Drug Application (NDA) for CNM-Au8 for ALS under an accelerated approval pathway by the end of June 2026. This follows a Type C meeting with the FDA scheduled for Q1 2026 to discuss biomarker data (NfL and GFAP) and survival benefits. A Phase 3 confirmatory trial (RESTORE-ALS) is planned to commence in H2 2026, contingent on funding.

Outlook: The company expects to continue incurring significant losses as it advances clinical programs. Management anticipates that current cash resources will not be sufficient to sustain operations for the next 12 months without additional financing.

Material Risks:

• Going Concern: The filing explicitly states substantial doubt about the company's ability to continue as a going concern beyond one year due to recurring losses and negative cash flows.
• Liquidity Constraints: The company is required to maintain at least $2.0 million in unrestricted cash to avoid acceleration of its Senior Secured Convertible Promissory Notes (SSCP Notes).
• Internal Controls: Management identified material weaknesses in internal control over financial reporting, specifically regarding the control environment, manual journal entries, and IT general controls.
• Regulatory Uncertainty: There is no assurance that the FDA will accept the proposed biomarkers as a surrogate endpoint for accelerated approval.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $5.2 million cash balance against the $2.0 million covenant requirement and projected burn rate for the next 12 months.
• Financing Plans: Confirm the status of the registered direct offering ($6.0 million proceeds) closed in January 2026 and any subsequent capital raises required to fund the planned Phase 3 trial.
• FDA Meeting Outcome: Monitor the minutes from the Q1 2026 Type C FDA meeting regarding the acceptance of NfL/GFAP biomarkers for the ALS NDA.
• Internal Control Remediation: Review progress on remediation plans for the identified material weaknesses in internal controls over financial reporting.
• Debt Covenants: Assess the risk of debt acceleration if the company fails to maintain the $2.0 million unrestricted cash balance.